Fatigue News and Research

RSS

Walgreens Flu Impact Report

The typical flu season always coincides with the busiest travel period of the year, and last season that spelled trouble for more than 3 million U.S. vacationers whose trips were interrupted by flu-related illness, the Walgreens Flu Impact Report suggests.

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

First Edition: October 11, 2011

Today's headlines include reports about how Mitt Romney taking heat from the other GOP hopefuls, with some of the fire focusing on his Massachusetts health overhaul.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Study identifies gene mutation responsible for higher frequency of Italian CDA II

Many of you might know that Congenital Dyserythropoietic Anemia type II (CDA II) is a rare blood disorder, due to a failure in final part of erythropoiesis. What will surprise you is the fact that some mutations responsible for the disease can be tracked 3.000 years back.

10 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.

6 Oct 2011

Mild stroke patients may live with hidden disabilities: Study

On the surface they appear unaffected, but people who have mild strokes may live with hidden disabilities, including depression, vision problems and difficulty thinking, according to a study released today at the Canadian Stroke Congress.

3 Oct 2011

Combination therapy improves outcomes for liver cancer patients: Study

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.

1 Oct 2011

Research roundup: What older patients really prize; DOD and the ACA

DOD Health Care: Cost Impact Of Health Care Reform And The Extension Of Dependent Coverage -- This study, mandated by Congress, assesses the financial impact of the federal health law on the Defense Department's budget.

1 Oct 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, cannot enjoy a normal lifestyle. "The aortic valve is a gatekeeper," says Marco Costa, MD, of University Hospitals (UH) Case Medical in Cleveland.

From Medtronic 1 Oct 2011

Lifespan researcher receives Ig Nobel Prize at Harvard University

Peter J. Snyder, Ph.D., vice president of research for Lifespan, received one of 10 Ig Nobel Prize awards during the annual ceremony last night at Harvard University.

1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

29 Sep 2011

Study links pain severity with depression

A new study in The Journal of Pain, published by the American Pain Society, www.ampainsoc.org, shows that changes in pain severity can predict subsequent depression severity and, likewise, a worsening change in depression is an equally strong predictor of subsequent pain severity.

29 Sep 2011

Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.

28 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

Columbia University receives CFI grant to investigate causes of chronic fatigue syndrome

The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.

28 Sep 2011